

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

To The Board of Directors of Dr. Lal PathLabs Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Dr. Lal PathLabs Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June, 2021 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the entities listed in Annexure A
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Deloitte Haskins & Sells LLP

6. The consolidated unaudited financial results includes the interim financial information/ financial results of four subsidiaries which have not been reviewed by their auditors, whose interim financial information/ financial results reflect total revenue of Rs. 50 million for the quarter ended 30 June, 2021, total loss after tax of Rs. 1 million for the quarter ended 30 June, 2021 and total comprehensive loss of Rs. 1 million for the quarter ended 30 June, 2021 respectively, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information/ financial results are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information/ financial results certified by the Management.

For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Jitendra Agarwal
Partner
(Membership No. 87104)
(UDIN: 21087104AAAAEV1419)

Place: New Delhi
Date: 30 July, 2021

Deloitte Haskins & Sells LLP

Annexure A

List of entities consolidated

a) **Parent Company:** Dr. Lal PathLabs Limited


b) **Subsidiaries held directly**

S. No.	Name of the Entity
1	Paliwal Diagnostics Private Limited
2	Paliwal Medicare Private Limited
3	APL Institute of Clinical Laboratory & Research Private Limited
4	Dr. Lal PathLabs Nepal Private Limited
5	Dr. Lal PathLabs Bangladesh Pvt. Ltd.
6	Dr. Lal Ventures Private Limited
7	Pathlabs Unifiers Private Limited
8	Dr. Lal PathLabs Kenya Private Limited

c) **Subsidiaries held indirectly**

S. No.	Name of the Entity
1	Centrapath Labs Private Limited
2	APRL PathLabs Private Limited
3	Chanre Laboratory Private Limited (w.e.f 25 January, 2021)





Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC065388

Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085, New Delhi

Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon – 122 001, Haryana

Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

Statement of Consolidated Unaudited Financial Results for the quarter ended 30 June, 2021

(Rs. in million except as stated)


Particulars	3 months ended 30 June, 2021	Preceding 3 months ended 31 March, 2021	Corresponding 3 months ended 30 June, 2020	Previous year ended 31 March, 2021
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Income		(See note iv)		
(a) Revenue from operations	6,066	4,310	2,660	15,813
(b) Other income	141	135	114	513
Total Income	6,207	4,445	2,774	16,326
2 Expenses				
(a) Cost of materials consumed	1,451	1,033	759	3,973
(b) Employee benefits expense	864	761	595	2,737
(c) Finance costs	46	44	37	160
(d) Depreciation and amortisation expense	192	203	179	772
(e) Fees to collection centers/channel partners	921	585	293	2,043
(f) Other expenses	940	711	530	2,697
Total expenses	4,414	3,337	2,393	12,382
3 Profit before tax	1,793	1,108	381	3,944
4 Tax expense				
(a) Current tax	521	256	121	1,021
(b) Deferred tax	(65)	1	(24)	(42)
Total tax expense	456	257	97	979
5 Profit for the period (A)	1,337	851	284	2,965
6 Other comprehensive income				
Items that will not be reclassified to profit or loss				
-Remeasurement of the defined benefit obligations	(2)	(10)	(12)	(9)
-Income tax in relation to the items that will not be reclassified to profit or loss	1	2	3	2
Items that may be reclassified to profit or loss				
-Exchange differences on translation of foreign operations	-	-	-	(1)
Total other comprehensive income/ (loss) (B)	(1)	(8)	(9)	(8)
7 Total comprehensive income (A+B)	1,336	843	275	2,957
Profit for the period attributable to:				
Owners of the Company	1,312	834	284	2,916
Non-controlling interest	25	17	-	49
	1,337	851	284	2,965
Other comprehensive income for the period attributable to:				
Owners of the Company	(1)	(8)	(9)	(8)
Non-controlling interest	-	-	-	-
	(1)	(8)	(9)	(8)
Total comprehensive income for the period attributable to:				
Owners of the Company	1,311	826	275	2,908
Non-controlling interest	25	17	-	49
	1,336	843	275	2,957
8 Paid-up equity share capital (Face value of Rs. 10 per share)	833	833	833	833
9 Other equity				11,617
10 Earnings per share (Rs.) (Face value of Rs. 10 per share)(not annualised)				
-Basic	15.87	10.10	3.45	35.33
-Diluted	15.84	10.07	3.44	35.25

Dr. Lal PathLabs Limited

Notes:

- i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 30 July, 2021. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter ended June 30, 2021 and they have expressed an unmodified conclusion on the aforesaid results.
- ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group').
- iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- iv. Figures for the quarter ended 31 March, 2021 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December, 2020, which were subjected to limited review.
- v. The Board of Directors of the Parent Company have approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 30 July, 2021.
- vi. The results of quarter ended June 30, 2021 are not strictly comparable with the results of the previous quarter and corresponding previous quarter, due to resurgent wave of COVID -19 in quarter ended June 30, 2021 and nationwide lockdown in the corresponding previous quarter.
- vii. The Board of Directors of the Parent Company and one of the subsidiary company's "APL Institute of Clinical Laboratory & Research Private Limited" ("APL") in their respective board meetings held on 3 February, 2020 had approved the "Scheme of Amalgamation" of APL with the Parent Company w.e.f. 1 April, 2020 (the appointed date). As per the said scheme the undertaking of APL shall stand transferred to and vested in the Company on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the shareholders, National Company Law Tribunal and other statutory approvals.
- viii. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.
- ix. The Indian Parliament has approved the Code on Social Security, 2020 ('the Code') which, inter alia, deals with employee benefits during employment and post-employment. The Code has been published in the Gazette of India. The effective date of the Code is yet to be notified. In view of this, the Group is in the process of assessing the impact of the relevant provisions.

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited


(Hony) Brig. Dr. Arvind Lal
Executive Chairman

Place: Gurugram
Date: 30 July, 2021



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

To The Board of Directors of Dr. Lal PathLabs Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Dr. Lal PathLabs Limited** ("the Company"), for the quarter ended 30 June, 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins & Sells LLP**

Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Jitendra Agarwal
(Partner)

(Membership No. 87104)
(UDIN: 21087104AAAAEU6496)

Place: New Delhi
Date: 30 July 2021

Statement of Standalone Unaudited Financial Results for the quarter ended 30 June, 2021

(Rs. in million except as stated)

Particulars	3 months ended 30 June, 2021	Preceding 3 months ended 31 March, 2021	Corresponding 3 months ended 30 June, 2020	Previous year ended 31 March, 2021
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		(See note iii)		
1 Income				
(a) Revenue from operations	5,649	4,041	2,550	14,905
(b) Other income	135	131	111	513
Total Income	5,784	4,172	2,661	15,418
2 Expenses				
(a) Cost of materials consumed	1,337	965	730	3,739
(b) Employee benefits expense	808	712	563	2,574
(c) Finance costs	44	39	35	148
(d) Depreciation and amortisation expense	168	179	164	698
(e) Fees to collection centers/channel partners	900	572	288	2,007
(f) Other expenses	875	658	496	2,511
Total expenses	4,132	3,125	2,276	11,677
3 Profit before tax	1,652	1,047	385	3,741
4 Tax expense				
(a) Current tax	490	244	119	985
(b) Deferred tax	(71)	16	(22)	(45)
Total tax expense	419	260	97	940
5 Profit for the period (A)	1,233	787	288	2,801
6 Other comprehensive income				
Items that will not be reclassified to profit or loss	(2)	(11)	(12)	(9)
-Remeasurement of the defined benefit obligations				
-Income tax in relation to the items that will not be reclassified to profit or loss	1	3	3	2
Total other comprehensive income/(loss) (B)	(1)	(8)	(9)	(7)
7 Total comprehensive income (A+B)	1,232	779	279	2,794
8 Paid-up equity share capital (Face value of Rs. 10 per share)	833	833	833	833
9 Other equity				11,338
10 Earnings per share (Rs.) (Face value of Rs. 10 per share) (not annualised)				
- Basic	14.93	9.52	3.50	33.93
- Diluted	14.89	9.50	3.49	33.85



Dr. Lal PathLabs Limited

Notes:

- i. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 30 July, 2021. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter ended June 30, 2021 and they have expressed an unmodified conclusion on the aforesaid results.
- ii. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- iii. Figures for the quarter ended 31 March, 2021 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December, 2020, which were subjected to limited review.
- iv. The Board of Directors of the company have approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 30 July, 2021.
- v. During the quarter ended 30 June, 2021, the Company has made a further investment of INR 45 million in its wholly owned subsidiary, PathLabs Unifiers Private Limited, through subscription of additional equity shares.
- vi. The results of quarter ended June 30, 2021 are not strictly comparable with the results of the previous quarter and corresponding previous quarter, due to resurgent wave of COVID - 19 in quarter ended June 30, 2021 and nationwide lockdown in the corresponding previous quarter.
- vii. The Board of Directors in their meeting held on 3 February, 2020 had approved the "Scheme of Amalgamation" of "APL Institute of Clinical Laboratory & Research Private Limited" ("APL") with the Company w.e.f. 1 April, 2020 (the appointed date). As per the said scheme the undertaking of APL shall stand transferred to and vested in the Company on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the shareholders, National Company Law Tribunal and other statutory approvals.
- viii. The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company's performance, allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore there is no reportable segment for the Company, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.
- ix. The Indian Parliament has approved the Code on Social Security, 2020 ('the Code') which, inter alia, deals with employee benefits during employment and post-employment. The Code has been published in the Gazette of India. The effective date of the Code is yet to be notified. In view of this, the Company is in the process of assessing the impact of the relevant provisions.

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited



(Hony) Brig. Dr. Arvind Lal
Executive Chairman

Place: Gurugram
Date: 30 July, 2021

